Literature DB >> 2737527

Clinical correlation of hormone receptor status in epithelial ovarian cancer.

S Masood1, J Heitmann, R C Nuss, G I Benrubi.   

Abstract

Cytoplasmic estrogen receptor (ER) and progesterone receptor (PR) levels were measured in ovarian epithelial carcinomas from 37 patients using a dextran-coated charcoal assay prior to any treatment. Sixty-eight percent of the tumors were ER positive, forty-nine percent were PR positive, forty-one percent were positive for both receptors, and twenty-seven percent were negative for both receptors. Receptor status in epithelial ovarian carcinomas was found to have no clinical significance when correlated with age, parity, race, cigarette smoking, surgical stage, histologic type, histologic grade, progression-free interval, or patient survival.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737527     DOI: 10.1016/0090-8258(89)90107-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.

Authors:  Luis Felipe Sallum; Luis Otavio Sarian; Liliana Lucci De Angelo Andrade; José Vassallo; Fernando Augusto Soares; Glauce Aparecida Pinto; Patrícia Andréia Ferreira; Sophie Derchain
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

2.  Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies.

Authors:  J Akahira; T Inoue; T Suzuki; K Ito; R Konno; S Sato; T Moriya; K Okamura; A Yajima; H Sasano
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

3.  Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.

Authors:  J-I Akahira; M Aoki; T Suzuki; T Moriya; H Niikura; K Ito; S Inoue; K Okamura; H Sasano; N Yaegashi
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.